性健康是宫颈癌的一个重要的生存问题。我们评估了患者报告的性健康结果以及与肿瘤学家评估的阴道毒性 (VT) 的相关性。这是一项针对接受根治性放化疗的 IB-IVA 期宫颈癌患者的前瞻性横断面研究，患者完成了社会人口统计调查问卷并以下患者报告结果 (PRO)：女性性功能指数 (FSFI)、女性性困扰量表修订版 (FSDS-R)、更年期评定量表 (MRS)、医院焦虑和抑郁量表 (HADS)。使用 CTCAE v4.0 评估 VT。使用描述性统计总结社会人口统计学、临床数据、PRO 和 VT；使用线性回归分析评估相关性。2018 年 8 月至 2022 年 4 月期间，对 73 名患者进行了分析。中位年龄为 49 岁（范围 25-81 岁），57.5% 诊断时有阴道受累，76.9% 有伴侣。 86.3% 的人报告性功能障碍（FSFI 评分≤26）、性困扰（FSDS-R≥11）、严重更年期症状（MRS≥17）、焦虑（HAD-焦虑>7）和抑郁（HAS-抑郁>7）分别为 54.5%、36.2%、46.6% 和 24.7%。据报道，2 级 VT 的发生率为 27.4%。 PRO 和 VT 之间没有发现显着关联。根据多变量分析、非伴侣状态、激素替代疗法的使用以及国际辐射单位和测量委员会 - 直肠阴道剂量 (ICRU-RV) > 65Gy 与较差的性健康相关 (p < 0.005)。性困扰、功能障碍和更年期症状的发生率很高。肿瘤学家评估的 VT 和 PRO 之间的不一致凸显了评估患者体验的重要性。应考虑积极治疗更年期症状并注意阴道放射治疗剂量。Crown 版权所有 © 2024。由 Elsevier Inc. 出版。保留所有权利。

Sexual health is an important survivorship issue in cervical cancer. We assessed patient-reported sexual health outcomes and correlations with oncologist-assessed vaginal toxicity (VT).This was a prospective, cross-sectional study of stage IB-IVA cervical cancer patients treated with definitive chemoradiation, who completed a socio-demographic questionnaire and the following patient-reported-outcomes (PROs): Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), Menopause Rating Scale (MRS), Hospital Anxiety and Depression Scale (HADS). VT was assessed using the CTCAE v4.0. Sociodemographic, clinical data, PROs and VT were summarized using descriptive statistics; correlations were evaluated using linear regression analyses.Between August 2018 and April 2022, 73 patients were analyzed. Median age was 49 (range 25-81), 57.5% had vaginal involvement at diagnosis and 76.9% were partnered. Sexual dysfunction (FSFI score ≤ 26), sexual distress (FSDS-R ≥ 11), severe menopausal symptoms (MRS ≥ 17), anxiety (HAD-Anxiety >7) and depression (HAS-Depression >7) were reported in 86.3%, 54.5%, 36.2%, 46.6% and 24.7%, respectively. Grade 2+ VT was reported in 27.4%. No significant associations were found between PROs and VT. On multivariable analysis, non-partnered status, use of hormone replacement therapy, and International Commission on Radiation Units and Measurements - rectovaginal dose (ICRU-RV) >65Gy were associated with worse sexual health (p < 0.005).Cervical cancer patients self-report high rates of sexual distress, dysfunction and menopause symptoms. Discordance between oncologist-assessed VT and PROs highlights the importance of evaluating the patient's experience. Proactive treatment of menopausal symptoms and attention to radiotherapy doses to the vagina should be considered.Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved.